Figure 1. About Dr Hemminki: Dr Akseli Eetu Hemminki studied Medicine and Medical Science at the University of Helsinki (Finland), where he completed his MD and PhD in 1999. He performed postdoctoral studies at the Department of Genetics at the University of Helsinki and in the Division of Human Gene Therapy at the University of Alabama at Birmingham (AL, USA), where he held positions as Research Assistant Professor, Director of Clinical Trials and Group Leader of Ovarian Cancer in the Division of Human Gene Therapy. 
In 2002 Dr. Hemminki returned to Finland as Group Leader of the Cancer Gene Therapy Group at the University of Helsinki, a position he still holds. He is also Docent of Cancer Biology and University Lecturer at the Haartman Institute at Helsinki University, as well as K Albin Johansson Research Professor at the Finnish Cancer Institute. In 2007 he completed the oncology specialization program at the University of Helsinki. Besides his research, Dr Hemminki has been working as senior physician at Helsinki University Central Hospital and Oncologist at International Cancer Center Docrates, Helsinki. 
Dr Hemminki is an active member of many professional societies and a regular speaker at national and international conferences in the fields of oncology and cancer immunotherapy. His research resulted in over 180 publications in peer-reviewed scientific journals, ten scientific books and book chapters, and several patents on viral vectors for immunotherapy. The research of the world-class Cancer Gene Therapy Group, headed by Dr Hemminki, was also the basis for his cofounding the biotech company Oncos Therapeutics in 2008. The company develops novel cancer immunotherapies and was awarded the BioFinland prize from Finnish Bioindustries in 2011. In addition, Dr Hemminki has received numerous awards and honors such as the Outstanding Young Investigator Award of the American Society of Gene Therapy in 2007 or the American Society of Clinical Oncology career development award in 2010.